comprehensive -WSS

comprehensive

author：explore 2025-09-29 21:29:20 - browse：5447

Pfizer and Moderna aren’t the only vaccine money-makers. Much of the revenue and profits from Covid-19 vaccines are flowing behind the scenes, going to the contract manufacturers and clinical-trial organizers that turn the shots from lab-bench theory to mass-produced reality.

Both AstraZeneca and Johnson & Johnson publicly committed to not profiting off their products during the pandemic — though AstraZeneca has reserved the right to declare the pandemic over on July 1, even if the World Health Organization has not. Pfizer and Moderna made no such pledge, with Pfizer expected to make $15 billion in vaccine-related revenue this year, while Moderna is forecasting $18.4 billion in vaccine sales.

Contractors hired to test and manufacture these vaccines have enjoyed a share of the profits without the same level of public scrutiny.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Doudna institute plans to 'cure hundreds of diseases' with CRISPR

Wikipedia

WSS

Heart disease and mental health: A look at cardiac psychology

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

JPM 2024: Nvidia claims we're in biological revolution. Are we?

The woman behind the Dana Farber

The woman behind the Dana Farber

Doulas covered by Medicaid under New York's new plan

hotspot

comprehensive

focus

Cancer drug shortages should be causing more outrage

Supreme Court wrestles with OxyContin maker's bankruptcy deal

The high cost of giving birth even with insurance

The nurse manager staffing crisis is hurting patients

How one medical school became remarkably diverse

GSK to buy asthma

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Health and fitness trackers are measuring the wrong things

Apple is now the first public company to be valued at $3 trillion

Caregivers of transplant patients call for more support, training

focus

DeSantis can now import cheaper drugs. But will Biden get credit?

FDA needs staff influx to meet gene therapy needs, Marks says

Fauci’s Covid grilling leads GOP to weigh foreign research rules

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

Congenital heart disease patients face new threat of heart failure

Roche to buy Carmot Therapeutics, developer of obesity drugs

Wikipedia

focus

hotspot

leisure time